NEW YORK, Dec. 19 – Cambridge Antibody Technology of Melbourn, UK, has licensed access to Incyte’s LifeSeq Gold database and obtained options for the rights to develop products based on the data, the companies said Wednesday.

CAT will use the data as well as cDNA clones Incyte provides to develop antibody therapeutic products. CAT also has the right to gain the exclusive licences from Incyte develop treatments aimed at protein targets in Incyte’s database.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

The World Health Organization has announced the members of its gene-editing committee, according to NPR.

DARPA is working on developing algorithms that gauge the credibility of research findings, Wired reports.

The American Society of Breast Surgeons recommends all women diagnosed with breast cancer be offered genetic testing, the Washington Post says.

In Science this week: comparison of modern, historical rabbit exomes uncovers parallel evolution after myxoma virus exposure; and more.